323 related articles for article (PubMed ID: 35958449)
1. A signature based on m6A pattern and tumor microenvironment infiltration in clear cell renal cell carcinoma.
Yang C; Yu T; Li Q; Xie F; Lin Q
Am J Transl Res; 2022; 14(7):4931-4947. PubMed ID: 35958449
[TBL] [Abstract][Full Text] [Related]
2. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
Meijing Z; Tianhang L; Biao Y
Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
[No Abstract] [Full Text] [Related]
3. m6A Methylation Patterns and Tumor Microenvironment Infiltration Characterization in Clear-Cell Renal Cell Carcinoma.
Ma T; Wang J; Liu X; Zhang W; Meng L; Zhang Y
Front Genet; 2022; 13():864549. PubMed ID: 35528542
[TBL] [Abstract][Full Text] [Related]
4. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.
Guo Y; Bai Y; Wang L; Xu Z; Wang X; Wang W
Medicine (Baltimore); 2022 Jul; 101(26):e29818. PubMed ID: 35777046
[TBL] [Abstract][Full Text] [Related]
5. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
Shen X; Zhong J; He J; Han J; Chen N
Front Immunol; 2022; 13():978092. PubMed ID: 36105819
[TBL] [Abstract][Full Text] [Related]
6. M6A-mediated molecular patterns and tumor microenvironment infiltration characterization in nasopharyngeal carcinoma.
Wang Y; Peng L; Wang F
Cancer Biol Ther; 2024 Dec; 25(1):2333590. PubMed ID: 38532632
[TBL] [Abstract][Full Text] [Related]
7. M6A Classification Combined With Tumor Microenvironment Immune Characteristics Analysis of Bladder Cancer.
Zhu H; Jia X; Wang Y; Song Z; Wang N; Yang Y; Shi X
Front Oncol; 2021; 11():714267. PubMed ID: 34604051
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma.
Qiu Y; Wang X; Fan Z; Zhan S; Jiang X; Huang J
Immun Inflamm Dis; 2021 Dec; 9(4):1596-1612. PubMed ID: 34432955
[TBL] [Abstract][Full Text] [Related]
9. Integrated Analyses of m6A Regulator-Based Signature on Its Clinical Application and Immunogenomic Landscape in Stomach Adenocarcinoma.
Zhang L; Zhang Q; Huang Z; Zhu M; Wang T; Zhu W; Wang X; Zhou X
Biomed Res Int; 2022; 2022():2053719. PubMed ID: 36193316
[TBL] [Abstract][Full Text] [Related]
10. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
11. N
Li C; Zhu M; Gao C; Lu F; Chen H; Liu J; Zhong W
Front Biosci (Landmark Ed); 2024 Jan; 29(1):33. PubMed ID: 38287827
[TBL] [Abstract][Full Text] [Related]
12. m6A Regulators Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization In Nasopharyngeal Carcinoma.
Liu Z; He J; Han J; Yang J; Liao W; Chen N
Front Immunol; 2021; 12():762243. PubMed ID: 35069534
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
14. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
15. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
16. ALDOB represents a potential prognostic biomarker for patients with clear cell renal cell carcinoma.
Shao Y; Wu B; Yang Z; Liu Z; Ma Y; Huang H; Liu Y; Wang Z; Hu W; Wang Y; Niu Y
Transl Androl Urol; 2023 Apr; 12(4):549-571. PubMed ID: 37181232
[TBL] [Abstract][Full Text] [Related]
17. Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy.
Zhao B; Xiang Z; Wu B; Zhang X; Feng N; Wei Y; Zhang W
Curr Pharm Des; 2023; 29(1):60-78. PubMed ID: 36503445
[TBL] [Abstract][Full Text] [Related]
18. Thyroid cancer risk prediction model using m6A RNA methylation regulators: integrated bioinformatics analysis and histological validation.
Zhou W; Lin J; Liu J; Zhang R; Fan A; Xie Q; Hong L; Fan D
Aging (Albany NY); 2023 Feb; 15(3):846-865. PubMed ID: 36791151
[TBL] [Abstract][Full Text] [Related]
19. Characterization of m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration in Ovarian Cancer.
Luo Y; Sun X; Xiong J
Front Cell Dev Biol; 2021; 9():794801. PubMed ID: 35087835
[No Abstract] [Full Text] [Related]
20. m6A regulator-mediated methylation modification patterns and tumor microenvironment immune infiltration with prognostic analysis in esophageal cancer.
Sheng G; Wang T; Gao Y; Wu H; Wu J
Sci Rep; 2023 Nov; 13(1):19670. PubMed ID: 37952076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
